Back to top
more

Redhill Biopharma (RDHL)

(Delayed Data from NSDQ)

$0.42 USD

0.42
193,132

-0.01 (-1.85%)

Updated Apr 24, 2024 03:52 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

RedHill Biopharma (RDHL) Up on New Patent for COVID-19 Candidate

by Zacks Equity Research

RedHill Biopharma (RDHL) receives a new patent from the United States Patent and Trademark Office for its investigational COVID-19 candidate, opaganib, in COVID-19 patients with pneumonia. Stock up.

    RedHill (RDHL) Up on Orphan Drug Tag for NTM Disease Drug

    by Zacks Equity Research

    RedHill's (RDHL) RHB-204 gets Orphan Drug designation from the European Commission for the treatment of nontuberculous mycobacteria (NTM) disease

    Redhill Biopharma Ltd. (RDHL) Could Find Support Soon, Here's Why You Should Buy the Stock Now

    by Zacks Equity Research

    Redhill Biopharma Ltd. (RDHL) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

    RedHill (RDHL) COVID Pneumonia Drug Meets Study Goal, Stock Up

    by Zacks Equity Research

    Redhill's (RDHL) opaganib achieves a significant reduction in mortality in hospitalized patients with severe COVID-19 pneumonia based on new data from the phase II/III study.

    RedHill (RDHL) Down on Unsatisfactory Data From COVID-19 Study

    by Zacks Equity Research

    RedHill (RDHL) posts preliminary top-line data from a phase II/III study evaluating opaganib in hospitalized patients with severe COVID-19 pneumonia. Stocks falls as the study fails to achieve its goal.

    RedHill's (RDHL) Opaganib Effective Against Kidney Fibrosis

    by Zacks Equity Research

    Opaganib, Redhill's (RDHL) candidate for COVID-19, achieves a significant reduction in kidney fibrosis in preclinical studies.

    Biotech Stock Roundup: REGN Gives Study Update, INCY Wins Drug Approval & More

    by Zacks Equity Research

    Regulatory and pipeline updates from Regeneron (REGN) and Incyte (INCY), among others, have been in focus in the biotech industry over the past week.

    Strength Seen in Redhill Biopharma Ltd. (RDHL): Can Its 5.4% Jump Turn into More Strength?

    by Zacks Equity Research

    Redhill Biopharma Ltd. (RDHL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

    RedHill (RDHL) Doses First Patient in Phase II/III COVID-19 Study

    by Zacks Equity Research

    RedHill (RDHL) doses first patient in phase II/III study of orally-administered RHB-107 (upamostat), an investigational new drug for patients with symptomatic COVID-19 who do not require hospital care.

    RedHill's (RDHL) RHB-204 Gets FDA Fast Track Designation

    by Zacks Equity Research

    RedHill (RDHL) gets Fast Track status from the FDA for the treatment of nontuberculous mycobacteria (NTM) disease.

    RedHill (RDHL) COVID-19 Drug Shows Promise in Mid-Stage Study

    by Zacks Equity Research

    RedHill's (RDHL) opaganib achieves greater improvement in reducing oxygen requirement compared to placebo in a phase II study evaluating it in patients hospitalized with COVID-19 pneumonia.

    Is the Options Market Predicting a Spike in RedHill Biopharma (RDHL) Stock?

    by Zacks Equity Research

    Investors need to pay close attention to RedHill Biopharma (RDHL) stock based on the movements in the options market lately.

    RedHill (RDHL) Expands Opaganib Manufacturing Capacity in US

    by Zacks Equity Research

    RedHill (RDHL) expands its manufacturing capacity to support the potential emergency use applications to be filed for opaganib to address severe COVID-19 pneumonia in the United States.

    RedHill (RDHL) to Begin Study on Second Coronavirus Candidate

    by Zacks Equity Research

    The FDA clears RedHill's (RDHL) IND filing for a phase II/III study on its second coronavirus candidate RHB-107 to treat patients with symptomatic COVID-19 who do not require hospitalization.

    RedHill (RDHL) Closes Enrollment for Phase II Coronavirus Study

    by Zacks Equity Research

    Redhill (RDHL) completes enrollment in the phase II study on opaganib in patients hospitalized with severe COVID-19 pneumonia.

    RedHill's (RDHL) RHB-204 Gets FDA Orphan Drug Designation

    by Zacks Equity Research

    RedHill (RDHL) gets Orphan Drug status from the FDA for the treatment of nontuberculous mycobacteria (NTM) disease.

    RedHill Gets Nod in Brazil for Coronavirus Study on Opaganib

    by Zacks Equity Research

    The Brazilian Health Regulatory Agency okays RedHill's (RDHL) to conduct a phase II/III study on opaganib for treating patients with severe COVID-19 infection and pneumonia. Stock up.

    RedHill (RDHL) to Study Opaganib for Severe Coronavirus in UK

    by Zacks Equity Research

    RedHill's (RDHL) CTA gets approval in the United Kingdom to start a phase II/III study on opaganib for patients hospitalized with severe COVID-19 infection and pneumonia.

    RedHill Files CTA for Coronavirus Study on Opaganib in Russia

    by Zacks Equity Research

    RedHill (RDHL) submits a Clinical Trial Application in Russia for a phase II/III study on opaganib to treat patients detected with severe COVID-19 infection and pneumonia. Stock up.

    Is Redhill Biopharma (RDHL) Stock Outpacing Its Medical Peers This Year?

    by Zacks Equity Research

    Is (RDHL) Outperforming Other Medical Stocks This Year?

    Is Redhill Biopharma (RDHL) Outperforming Other Medical Stocks This Year?

    by Zacks Equity Research

    Is (RDHL) Outperforming Other Medical Stocks This Year?

    RedHill's Oncology Candidate to be Tested for Coronavirus

    by Zacks Equity Research

    RedHill (RDHL) inks a deal with NIAID for non-clinical testing of its investigational candidate RHB-107 to evaluate its activity against COVID-19. Stock up.

    RedHill (RDHL) Soars: Stock Adds 9.2% in Session

    by Zacks Equity Research

    RedHill (RDHL) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

    Top Ranked Momentum Stocks to Buy for April 9th

    by Zacks Equity Research

    Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 9th

    Top Ranked Momentum Stocks to Buy for April 7th

    by Zacks Equity Research

    Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 7th